Conference Coverage

Cobomarsen shows early promise for treating ATLL


 

REPORTING FROM TCLF 2019

Safety

There were no dose-limiting toxicities, AE-related discontinuations, treatment-related grade 3/4 AEs, or new opportunistic infections observed.

“[I] have to say, in using this drug now for over a year in two of my patients – and that’s with weekly administration – we really haven’t seen anything as far as adverse events,” Dr. Foss said.

She noted that one patient has reported transient diarrhea after dosing.

Two serious AEs – febrile neutropenia and pyrexia – occurred in one patient, but neither of these events were considered related to cobomarsen. The AEs occurred after the patient had stopped cobomarsen, and both events resolved.

There were no on-treatment deaths. One patient (the one who received cobomarsen for 9 days) died from disease progression approximately 2 months after stopping cobomarsen and while on a different therapy.

Dr. Foss said, based on their results, she and her colleagues are hoping to accrue more ATLL patients in this trial.

The trial is sponsored by miRagen Therapeutics. Dr. Foss is a cochair of the T-cell Lymphoma Forum. The T-cell Lymphoma Forum is organized by Jonathan Wood & Associates, which is owned by the same company as this news organization.

Pages

Recommended Reading

Combo treatment may improve quality of life in CTCL
MDedge Hematology and Oncology
Imaging, radiotherapy clarified in new PMBCL guidelines
MDedge Hematology and Oncology
Novel bispecific CAR shows promise in B-cell malignancies
MDedge Hematology and Oncology
Umbralisib gains FDA breakthrough designation for MZL
MDedge Hematology and Oncology
IPH4102 on fast track for Sézary syndrome
MDedge Hematology and Oncology
Applying ECHELON-2 results to clinical practice
MDedge Hematology and Oncology
GALLIUM: MRD response correlates with outcomes in follicular lymphoma
MDedge Hematology and Oncology
FDA grants BI-1206 orphan designation for MCL
MDedge Hematology and Oncology
Combo emerges as bridge to transplant in rel/ref PTCL
MDedge Hematology and Oncology
Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
MDedge Hematology and Oncology